Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $63.66 USD
Change Today +0.69 / 1.10%
Volume 511.0K
STJ On Other Exchanges
New York
As of 5:15 PM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

One St. Jude Medical Drive

St. Paul, MN 55117

United States

Phone: 651-756-2000

Fax: 651-756-3301

’s patented Linx AC, an anti-calcification treatment designed to increase the valve's durability by reducing tissue mineralization (hardening), which is one of the primary causes of valve deterioration. Valve Repair: The company also offers a complement of heart valve repair products, including two fully flexible and two semi-rigid rings, such as the Tailor flexible ring and the Attune flexible adjustable annuloplasty ring; and the SJM Séguin Semi-Rigid Ring and the SJM Rigid Saddle Ring. Annuloplasty rings are prosthetic devices used to repair diseased or damaged mitral and tricuspid heart valves. Transcatheter Aortic Valve Replacement: The company developed the Portico transcatheter aortic valve for a minimally invasive alternative to open heart surgery. The Portico transcatheter 23 mm aortic valve and the transfemoral delivery system received European CE Mark approval in 2012, and the 25 mm valve received European CE Mark approval in 2013. In addition, in 2014, the company initiated the U.S. IDE trial to evaluate the safety and efficacy of the Portico transcatheter aortic valve and delivery systems for patients with symptomatic severe aortic stenosis who are considered at high or extreme risk for open heart surgery. In September 2014, the company paused global implants of the Portico valve to ensure patient safety while further investigating reports of reduced leaflet mobility seen in the 4D CT imaging and transesophageal echo imaging. Closure Devices: Through the acquisition of AGA Medical, the company extended its portfolio to the transcatheter treatment of structural heart defects. Transcatheter closure offers pediatric and adult patients a minimally invasive alternative to surgery. The majority of this portfolio includes a line of occluder devices to treat congenital heart defects, including atrial septal defects, the most common congenital heart defect. The company’s portfolio includes the AMPLATZER Septal Occluder for closure of atrial septal defects (FDA approval and European CE Mark approval), the AMPLATZER Muscular VSD Occluder for closure of muscular ventricular septal defects (FDA approval and European CE Mark approval), and the AMPLATZER Duct Occluder for closure of patent ductus arteriosus (FDA approval and European CE Mark approval). In 2013, the company received FDA approval for the AMPLATZER Duct Occluder II (European CE Mark approval in 2008) for closure of patent ductus arteriosus, expanding the percutaneous treatment indication for patent ductus arteriosus. In addition to its portfolio of treatment options for congenital heart disease, the AMPLATZER portfolio also includes devices for patent foramen ovale (PFO) closure, sealing a hole in the septum between the right and left sides of the heart, and left atrial appendage closure to reduce the risk of ischemic stroke in patients with AF. Neuromodulation Products The company’s neuromodulation product offerings provide neurostimulation therapy in which an implantable device delivers electrical current to targeted anatomical structures. The company’s commercialized neurostimulation therapies include SCS, targeted SCS through its Spinal Modulation investment and distribution agreement and RFA for the treatment of chronic pain and deep brain stimulation (DBS) for treating the symptoms of Parkinson's disease, tremor and primary and secondary dystonia. A neurostimulation system consists of four components, such as an implantable pulse generator (IPG) that produces the electrical current and is implanted under the patient's skin; leads, which carry electrical impulses to the intended anatomical structure; an external patient remote control that enables the patient to control his or her therapy within prescribed ranges; and an external clinician programmer that is used to access all programming options of the implant to tailor therapy for the patient. The major application for neurostimulation therapy is for the management of chronic pain. This involves delivering electrical impulses through an implanted device (sometimes referred to as a ‘pacemaker for pain’) to the spinal cord. This stimulation is theorized to interfere with the transmission


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STJ:US $63.66 USD +0.69

STJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Edwards Lifesciences Corp $165.12 USD +1.45
Olympus Corp ¥4,945 JPY +30.00
Smith & Nephew PLC 1,121 GBp -12.00
Terumo Corp ¥3,980 JPY -20.00
Zimmer Biomet Holdings Inc $101.00 USD -0.29
View Industry Companies

Industry Analysis


Industry Average

Valuation STJ Industry Range
Price/Earnings 18.1x
Price/Sales 3.2x
Price/Book 4.5x
Price/Cash Flow 16.3x
TEV/Sales 1.9x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ST JUDE MEDICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at